Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.37 |
| ▸ | HTR2C | P28335 | 1/20 | 0.36 |
| ▸ | MAOA | P21397 | 3/20 | 0.36 |
| ▸ | MAOB | P27338 | 3/20 | 0.36 |
| ▸ | DRD2 | P14416 | 1/20 | 0.36 |
| ▸ | DRD1 | P21728 | 1/20 | 0.36 |
| ▸ | DRD4 | P21917 | 1/20 | 0.36 |
| ▸ | DRD5 | P21918 | 1/20 | 0.36 |
| ▸ | DRD3 | P35462 | 1/20 | 0.36 |
| ▸ | AHR | P35869 | 1/20 | 0.35 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | THRB | P10828 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29775334 | 0.87 | SIGMAR1 (0.41) | SIGMAR1TSHRCYP1A2HDAC9HTR2C | |
| SCHEMBL22717802 | 0.87 | SIGMAR1 (0.41) | SIGMAR1TSHRCYP1A2HDAC9HTR2C | |
| SCHEMBL15720982 | 0.82 | TSHR (0.41) | SIGMAR1TSHR | |
| SCHEMBL13437222 | 0.80 | TSHR (0.49) | SIGMAR1TSHRCYP1A2HTR2CMAOA | |
| SCHEMBL11706445 | 0.80 | ALDH1A1 (0.41) | SIGMAR1TSHR | |
| SCHEMBL31012316 | 0.80 | SIGMAR1 (0.34) | SIGMAR1TSHRCYP1A2HDAC9MAOA | |
| SCHEMBL30529399 | 0.80 | ALDH1A1 (0.41) | SIGMAR1TSHR | |
| SCHEMBL21788503 | 0.80 | HTR2C (0.40) | SIGMAR1HTR2CMAOBDRD2AHR | |
| SCHEMBL29610357 | 0.80 | HTR2C (0.40) | SIGMAR1HTR2CMAOBDRD2AHR | |
| SCHEMBL24424921 | 0.78 | TDP1 (0.43) | HTR2CAHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250296076-A1 | MULTIDENTATE PHOSPHITE LIGANDS, CATALYTIC COMPOSITIONS CONTAINING SUCH LIGANDS, AND CATALYTIC PROCESSES UTILIZING SUCH CATALYTIC COMPOSITIONS | INV NYLON CHEMICALS AMERICAS, LLC | 2025-09-25 | — | — | US | disclosed |
| CN-114380866-A | Organic electroluminescent material and device | 环球展览公司 | 2022-04-22 | — | — | CN | disclosed |
| US-8969628-B2 | Method for enriching a homogeneous catalyst from a process flow | EVONIK DEGUSSA GMBH (DE) | 2015-03-03 | — | — | US | disclosed |
| EP-2401078-B1 | METHOD FOR ENRICHING A HOMOGENOUS CATALYST FROM A PROCESS FLOW | EVONIK DEGUSSA GMBH (DE) | 2013-10-23 | — | — | EP | disclosed |
| US-20120046503-A1 | METHOD FOR ENRICHING A HOMOGENEOUS CATALYST FROM A PROCESS FLOW | EVONIK OXENO GMBH (DE) | 2012-02-23 | — | — | US | disclosed |
| EP-2401078-A1 | METHOD FOR ENRICHING A HOMOGENOUS CATALYST FROM A PROCESS FLOW | Evonik Oxeno GmbH (DE) | 2012-01-04 | — | — | EP | disclosed |
| WO-2010097376-A1 | METHOD FOR ENRICHING A HOMOGENOUS CATALYST FROM A PROCESS FLOW | EVONIK OXENO GMBH (DE) | 2010-09-02 | — | — | WO | disclosed |
| US-20050256308-A1 | Spiro compounds, medicinal compositions containing the same and intermediates of the compounds | DAINIPPON PHARMACEUTICAL CO., LTD. (JP) | 2005-11-17 | — | — | US | disclosed |
| EP-1559707-A1 | SPIRO COMPOUNDS, MEDICINAL COMPOSITIONS CONTAINING THE SAME AND INTERMEDIATES OF THE COMPOUNDS | Dainippon Pharmaceutical Co., Ltd. (JP) | 2005-08-03 | — | — | EP | disclosed |
| US-6288206-B1 | MIXED WITH DYE; HEAT RESISTANCE, STABILITY; ELECTROOPTICS; | MOLECULAR OPTOELECTRONICS CORPORATION | 2001-09-11 | — | — | US | disclosed |
| WO-2000054103-A1 | CHIRAL POLYMER COMPOSITIONS EXHIBITING NONLINEAR OPTICAL PROPERTIES | MOLECULAR OPTOELECTRONICS CORPORATION (US) | 2000-09-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250296076-A1 | MULTIDENTATE PHOSPHITE LIGANDS, CATALYTIC COMPOSITIONS CONTAINING SUCH LIGANDS, AND CATALYTIC PROCESSES UTILIZING SUCH CATALYTIC COMPOSITIONS | PHOSPHO1, PPA1, PNKP | SIGMAR1 3776/4885TSHR 2871/4885CYP1A2 3778/4885 |
| US-20050256308-A1 | Spiro compounds, medicinal compositions containing the same and intermediates of the compounds | ESRRA, ESR1, BRCA1 | SIGMAR1 222/4885TSHR 120/4885CYP1A2 1483/4885 |
| US-20120046503-A1 | METHOD FOR ENRICHING A HOMOGENEOUS CATALYST FROM A PROCESS FLOW | PARG, PHOSPHO1, COG6 | SIGMAR1 2870/4885TSHR 4505/4885CYP1A2 3899/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.